Hint mode is switched on Switch off
For swift navigation between sections

Maze Therapeutics

PDF download

Choose all Reset all
Download Cancel
Organization name
Maze Therapeutics, Inc
Country name
USA
Country of registration
USA
Industry
Pharmaceutical Preparation and Biotechnology
Public debt
-
Welcome to Cbonds
New to Cbonds? · Take a 90-second tour of the platform.

Discover what you can do with Cbonds

Everything you need for fixed income research and monitoring.

  • 00:23 Coverage
  • 00:40 Bond screener
  • 00:54 Parameters
  • 01:10 Watchlist, Mobile app
  • 01:15 Excel Add-in
Unlock data Watch full tour

Latest data on

Get access to the largest financial database

Try in 7-days Demo access

Free for company representative

  • Evaluate advanced analytical tools
  • Get full online access to the database
  • Try our powerful bond screener
  • Track bond prices from 400+ sources

Get access to the largest financial database

Representative of the company 7 days FREE trial

Professional access to the data

Private investor

Individual access

Quotes

Request sent
Access denied
Send request
Quotes provided by information providers are indicative in nature

Profile

Maze Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in harnessing the power of human genetics to develop novel, small molecule precision medicines for patients living with renal, cardiovascular, and related metabolic, or CVRM diseases. Its pipeline includes Compass platform, which allows to identify and characterize genetic variants in disease and then link those variants to the biological pathways that drive disease in specific patient groups through a process to refer a variant functionalization.

Awards

News

08/06/2026 Maze Therapeutics: Submission Of Matters To A Vote Of Security Holders
21/04/2026 Maze Therapeutics: Other Events, Financial Statements And Exhibits
24/03/2026 Maze Therapeutics: Results Of Operations And Financial Condition, Departure Of Directors Or Certain Officers; Election Of Directors; Appointment Of Certain Officers; Compensatory Arrangements Of Certain Officers, Regulation Fd, Financial Statements And Exhibits
02/02/2026 Maze Therapeutics: Entry Into A Material Definitive Agreement, Termination Of A Material Definitive Agreement, Creation Of A Direct Financial Obligation Or An Obligation Under An
10/09/2025 Maze Therapeutics: Entry Into A Material Definitive Agreement
All organization news

Documentation

IFRS/US GAAP reports

2026
I q eng
2025
I q eng
II q eng
III q eng
IV q eng
Show all Hide
Authorization required
You need to request access

Stocks

Public debt by currencies

Show more Hide

Codes

  • SIC
    2836 BIOLOGICAL PRODUCTS, (NO DISGNOSTIC SUBSTANCES)
  • NACE
    *** ***
  • NAICS
    *** ***
  • CIK
    0001842295
Registration is required to get access.